Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

British American Tobacco

Enterprise Products Partners

Magellan Midstream Partners

Just because the S&P 500 is 40% historically overvalued, doesn't mean you can't still find plenty of Buffett style "fat pitch" high-yield blue-chip bargains. 9/12 quality blue-chip BTI yields a safe 7.2%, is 51% undervalued, and analysts expect it could deliver 5-year total returns of 20.5% CAGR, 7.3X that of the S&P 500.

4 Buffett Fat Pitch High-Yield Blue-Chip Bargains Set To Soar

Aurora Cannabis

Cronos Group

GW Pharmaceuticals

Medicinal cannabis is no longer speculative. There are truly impactful treatments out there, as well as investment-worthy marijuana stocks.

7 Medical Marijuana Stocks for a Healthcare Revolution

Ford Motor Company

Gogo

Goldman Sachs

Nautilus

QUALCOMM

AT&T

Almost everyone likes cheap stocks, because as investors, we don't like to overpay. Some are value traps, while others are treasure chests.

7 Cheap Stocks to Buy Before the Market Realizes their Worth

NORTH CHICAGO, Ill., Dec. 6, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), today announced results from a long-term integrated analysis of two Phase 3 clinical studies and additional pooled analysis evaluating the effect of IMBRUVICA (ibrutinib) based therapies for the first-line treatment of...

Combined Data from Multiple Phase 3 Studies of IMBRUVICA® (ibrutinib) Show Efficacy and Safety in High-Risk, Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Real-World Data Indicating Low Biomarker Testing Rates for These Patients

Bristol-Myers

Pfizer

The Oracle of Omaha knows a good bargain when he sees one.

3 Value Stocks Warren Buffett Owns That You Should Consider Buying Too

NORTH CHICAGO, Ill., Dec. 5, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new, updated results from the Phase 3 MURANO and CLL14 clinical trials evaluating VENCLEXTA®/VENCLYXTO® (venetoclax) fixed duration treatment combinations at the virtual 62nd American Society of...

AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® (venetoclax) in Chronic Lymphocytic Leukemia (CLL)

NORTH CHICAGO, Ill., Dec. 5, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial evaluating IMBRUVICA® (ibrutinib) in combination with VENCLEXTA®/VENCLYXTO® (venetoclax) in previously untreated patients with chronic...

IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows High Rates of Disease-Free Survival One Year Post-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

Abbott Labs

Johnson & Johnson

These dividend stocks continue to outperform thier competition in yielding higher and consistent returns despite the impact of the pandemic The post 3 Dividend Stocks for Big Total Returns in 2021 appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets

3 Dividend Stocks for Big Total Returns in 2021

AbbVie Inc. (ABBV) Presents at Piper Sandler 32nd Annual Healthcare Conference (Transcript)

AbbVie (ABBV) signs a global deal with Frontier Medicines to make innovative therapies and E3 degraders against difficult-to-drug targets.

AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier

AbbVie (ABBV) Management on Evercore ISI 3rd Annual HealthCONx Conference

Inovio Pharmaceuticals

Novavax

Regeneron Pharmaceuticals

Now that companies such as Pfizer, Moderna and AstraZeneca have emerged with viable vaccines against Covid-19, the hype around many pharmaceutical stocks is fading. Here are four stocks investors should be weary of in the weeks ahead.

4 Pharmaceutical Stocks That Aren't Worth Their Outsized 2020 Gains

Merck

Berkshire's latest filing revealed the Oracle of Omaha and his team opening new positions in four pharma giants as of late. From a quality standpoint, all companies seem like a natural fit considering Buffett's reported preference for wide-moat businesses.

Buffett Buys Pharma: Two Out Of Four Seem Compelling

Gilead Sciences

Should you buy these drugmaker stocks for their juicy dividend yields?

3 Pharma Stocks With Dividends Above 4% to Buy Now

AbbVie stock is up 18% since the start of the year and it has gained around 62% from its March lows. Despite the recent rally, AbbVie could offer an upside in the near term, as the company's revenues in the last three quarters have grown by 30%, primarily aided by the Allergan acquisition.

Despite A 65% Rally AbbVie Stock Looks Like It Can Gain More

Autodesk

Cisco Systems

Dominion Energy

Duke Energy

Home Depot

Prudential Financial

Southern Company

Unum Group - 6.25% NT REDEEM 15/06/2058 USD 25

Top five holdings add up to 50% of my portfolio. Portfolio currently yields approximately 3.91%.

Eighth Review Of My Dividend Portfolio

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock?

AbbVie (ABBV) Up 30% Since Last Earnings Report: Can It Continue?

Despite solid gains in pharma sales and profits, Big Pharma's overall share value has pretty much stagnated over the past five years—but better days appear to be ahead, in my opinion.

Berkshire Hathaway Makes Big Bet on Pharma

The stock has a high yield -- and it also has something even more important.

Is AbbVie a Great Dividend Stock?

Citigroup

Citizens Financial Group

CVS Health

Chevron

Exelon

Diamondback Energy

Marathon Petroleum

NRG Energy

Realty Income Corp

Phillips 66

Valero Energy

Verizon

Williams

In October and July, Kiplinger Today listed Analyst and Kiplinger favorite dividend stocks. Analyst October favorites numbered 25, plus 15 from Kiplinger, with one repeated left 39 total. These 39 stocks ranged from 1.42% to 8.74% in annual yield and ranged from 0.13% to 33.33% in one-year price target upsides per brokers 11/25/20.

A Dividend Cornucopia Of 39 November Kiplinger/Analyst Favorites

Bank of America

General Motors

Kroger

Liberty Latin America

Snowflake

T-Mobile US

In this article we'll run through the Top 10 Stocks Warren Buffett Just Bought. If you're in a hurry to see the hedge fund legend's highest conviction new stock purchases, you can jump straight to the Top 5 Stocks Warren Buffett Just Bought .

Top 10 Stocks Warren Buffett Just Bought

Walgreens

By Bob Ciura with Sure Dividend. The U.S. stock market has come roaring back from the lows seen in March and April, but the broader economy remains on unstable footing.

3 Dividend Aristocrats For Safe Dividends And High Total Returns

News for AbbVie Stock (ABBV)